To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Adam Schechter successfully led ...
StockStory.org on MSN
The 5 most interesting analyst questions from Labcorp’s Q1 earnings call
Labcorp’s first quarter was marked by continued growth in both its Diagnostics and Biopharma Laboratory Services businesses, ...
The pandemic provided an unprecedented growth opportunity in diagnostic testing. COVID-19 tests took off, first, at testing sites — and later at home, Labcorp (LH) CEO Adam Schechter told Yahoo ...
Labcorp CEO Adam Schechter gives Barron’s a rundown of the diagnostic giant’s technology-first transformation.
Profit outlook tops Wall Street estimates amid strong diagnostics demand Peer growth trends also benefiting Quest Diagnostics CEO Adam Schechter cites continued growth focus for 2026 Analyst estimates ...
Labcorp is raising its 2026 guidance, buoyed by demand across its diagnostics and central laboratory businesses. | Labcorp is ...
Earnings call Labcorp reported 7% revenue growth and 13% adjusted EPS growth for FY25, with Q4 EPS up 18% YoY. Margin expanded 120bps in Q4 and over 50bps for the year. 2026 guidance calls for 5.4% ...
April 30 () - Labcorp raised its full-year profit and revenue forecast on Thursday after posting quarterly results above ...
DENVER, Sept. 13, 2022 /PRNewswire/ -- DaVita Inc. announced today that its Board of Directors appointed a new independent director, Adam H. Schechter, to join the Board, effective September 20, 2022.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results